Perioperative Outcomes of Uniportal Versus Three-port Video-assisted Thoracoscopic Surgery in Lung Cancer Patients Aged ≥75 years old:  A Cohort Study

Author:

Mi Xingqi1,Dai Zhangyi1,Liu Chengwu1,Mei Jiandong1,Zhu Yunke1,Liu Lunxu1,Pu Qiang1

Affiliation:

1. Sichuan University

Abstract

Abstract Background Increasing attention has been raised on the surgical option for lung cancer patients aged ≥75 years, however, few studies have focused on whether uniportal video-assisted thoracoscopic surgery (VATS) is safe and feasible for these patients. This study aimed to evaluate short-term results of uniportal versus three-port VATS for the treatment of lung cancer patients aged ≥75 years. Methods We retrospectively evaluated 582 lung cancer patients (≥75 years) who underwent uniportal or three-port VATS from August 2007 to August 2021 based on the Western China Lung Cancer Database. The baseline and perioperative outcomes between uniportal and three-port VATS were compared in the whole cohort (WC) and the patients undergoing lobectomy (lobectomy cohort, LC) respectively. ResultsIntraoperative blood loss was significantly less in the uniportal than three-port LC (50 mL vs. 83 mL, P=0.007) and was also relatively less in the uniportal than three-port WC (50 mL vs. 75 mL, P=0.05). In addition, in WC and LC, there were no significant differences between uniportal and three-port cohorts in terms of operation time, the rate of conversion to thoracotomy during surgery, nodal treatments (dissection or sampling or not), the overall number of lymph nodes and stations dissected, postoperative complications, volume and duration of postoperative thoracic drainage, hospital stay after operation and hospitalization expenses (P>0.05). Conclusions There were no significant differences in short-term outcomes between uniportal and three-port VATS for lung cancer patients (≥75 years), except significantly less intraoperative blood loss was found in uniportal LC (P<0.05). It is reasonable to indicate that uniportal VATS is a safe, feasible and effective operation procedure for lung cancer patients aged ≥75 years.

Publisher

Research Square Platform LLC

Reference21 articles.

1. Cancer incidence and mortality in China, 2016;Zheng R;Journal of the National Cancer Center,2022

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA: a cancer journal for clinicians,2021

3. Advances in systemic therapy for non-small cell lung cancer;Miller M;BMJ (Clinical research ed),2021

4. Survival After Thoracoscopic Surgery or Open Lobectomy: Systematic Review and Meta-Analysis;Hernandez-Vaquero D

5. Uniportal versus three-port video-assisted thoracoscopic surgery for non-small cell lung cancer: A retrospective study;Li T;Thoracic cancer,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3